National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 418081

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 3/11/2011

VAERS ID: 418081
VAERS Form:
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / - UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 6/14/2014

VAERS ID: 418081 Before After
VAERS Form:
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / - UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 4/14/2017

VAERS ID: 418081 Before After
VAERS Form:
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / - UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 9/14/2017

VAERS ID: 418081 Before After
VAERS Form:(blank) 1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / - UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 2/14/2018

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 6/14/2018

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 8/14/2018

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 9/14/2018

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 10/14/2018

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 8/14/2019

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (ZOSTAVAX) ZOSTER LIVE (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 12/24/2020

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER LIVE (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 12/30/2020

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER LIVE (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 5/7/2021

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER LIVE (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.


Changed on 5/14/2021

VAERS ID: 418081 Before After
VAERS Form:1
Age:50.0
Sex:Female
Location:Unknown
Vaccinated:2010-10-01
Onset:2010-10-01
Submitted:2011-03-04
Entered:2011-03-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER LIVE (ZOSTAVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Death, Haematoma

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died:2010-10-01
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? Yes
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:     Extended hospital stay? No
Previous Vaccinations:
Other Medications: COUMADIN
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data: Unknown
CDC 'Split Type': WAES1102USA03152

Write-up: Information has been received from a doctor of pharmacy concerning a female patient in her 50''s, who in October 2010, was vaccinated with a 0.65 ml dose of ZOSTAVAX (Merck) (Lot # not reported). Concomitant therapy included COUMADIN. The pharmacist reported that the patient received a shot of the ZOSTAVAX (Merck) and then was rushed to the hospital with a hematoma. After being admitted to the hospital the patient passed away, in October 2010, "a week after her shot". The pharmacist was not sure if it was due to the ZOSTAVAX (Merck) or not, and she was also not sure of the length of time between the patient getting the ZOSTAVAX (Merck) and being to the hospital. The pharmacist considered that the hematoma and that the patient "passed away" to be life threatening. Additional information has been requested.

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=418081&WAYBACKHISTORY=ON


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166